PE20221829A1 - Inhibicion de integrina alfa4 beta7 humana - Google Patents

Inhibicion de integrina alfa4 beta7 humana

Info

Publication number
PE20221829A1
PE20221829A1 PE2022000633A PE2022000633A PE20221829A1 PE 20221829 A1 PE20221829 A1 PE 20221829A1 PE 2022000633 A PE2022000633 A PE 2022000633A PE 2022000633 A PE2022000633 A PE 2022000633A PE 20221829 A1 PE20221829 A1 PE 20221829A1
Authority
PE
Peru
Prior art keywords
alkyl
inhibition
acid
human integrin
integrin alpha4
Prior art date
Application number
PE2022000633A
Other languages
English (en)
Spanish (es)
Inventor
Matthew G Bursavich
Dan Cui
James E Dowling
Kristopher N Hahn
Bryce A Harrison
fu-yang Lin
Blaise S Lippa
Bruce N Rogers
Dawn M Troast
Cheng Zhong
Kyle D Konze
Aleksey I Gerasyuto
Byungchan Kim
Salma Rafi
Tyler Day
Eugene Hickey
Evelyne Houang
Robert Zahler
Original Assignee
Morphic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic Inc filed Critical Morphic Therapeutic Inc
Publication of PE20221829A1 publication Critical patent/PE20221829A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Radio Relay Systems (AREA)
  • Air Conditioning Control Device (AREA)
PE2022000633A 2019-10-16 2020-10-16 Inhibicion de integrina alfa4 beta7 humana PE20221829A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962916062P 2019-10-16 2019-10-16
PCT/US2020/055986 WO2021076890A1 (en) 2019-10-16 2020-10-16 INHIBITING HUMAN INTEGRIN α4β7

Publications (1)

Publication Number Publication Date
PE20221829A1 true PE20221829A1 (es) 2022-11-29

Family

ID=73198501

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000633A PE20221829A1 (es) 2019-10-16 2020-10-16 Inhibicion de integrina alfa4 beta7 humana

Country Status (37)

Country Link
US (3) US11104661B1 (enExample)
EP (3) EP4045039B1 (enExample)
JP (7) JP7437495B2 (enExample)
KR (2) KR20220102669A (enExample)
CN (3) CN119192137A (enExample)
AR (1) AR120244A1 (enExample)
AU (2) AU2020366435A1 (enExample)
BR (1) BR112022007284A2 (enExample)
CA (1) CA3154269A1 (enExample)
CL (1) CL2022000959A1 (enExample)
CO (1) CO2022005759A2 (enExample)
CR (1) CR20220205A (enExample)
CU (1) CU20220027A7 (enExample)
DK (1) DK4045039T3 (enExample)
DO (2) DOP2022000081A (enExample)
EC (1) ECSP22038978A (enExample)
ES (1) ES3035561T3 (enExample)
FI (1) FI4045039T3 (enExample)
HR (1) HRP20250749T1 (enExample)
HU (1) HUE071814T2 (enExample)
IL (2) IL319053A (enExample)
LT (1) LT4045039T (enExample)
MA (1) MA57399B1 (enExample)
MD (1) MD4045039T2 (enExample)
MX (1) MX2022004406A (enExample)
PE (1) PE20221829A1 (enExample)
PH (1) PH12022550886A1 (enExample)
PL (1) PL4045039T3 (enExample)
PT (1) PT4045039T (enExample)
PY (1) PY2065718A (enExample)
RS (1) RS66976B1 (enExample)
SI (1) SI4045039T1 (enExample)
TW (7) TWI802477B (enExample)
UA (1) UA130059C2 (enExample)
UY (1) UY38926A (enExample)
WO (3) WO2021076890A1 (enExample)
ZA (2) ZA202203872B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112312910A (zh) 2018-04-12 2021-02-02 莫菲克医疗股份有限公司 人整合素α4β7拮抗剂
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
US11266643B2 (en) 2019-05-15 2022-03-08 Chemocentryx, Inc. Triaryl compounds for treatment of PD-L1 diseases
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物
CR20220216A (es) 2019-10-16 2023-01-09 Chemocentryx Inc Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
AU2020366435A1 (en) * 2019-10-16 2022-04-21 Morphic Therapeutic, Inc. Inhibiting human integrin α4β7
US11713307B2 (en) 2019-10-16 2023-08-01 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
US20250195485A1 (en) * 2021-12-27 2025-06-19 Xizang Haisco Pharmaceutical Co., Ltd. Propionic acid derivative and medical use thereof
KR20250061759A (ko) 2022-09-09 2025-05-08 시젱 하이스코 파마수티칼 씨오., 엘티디. 프로피온산 유도체 및 이의 의약에서의 응용
WO2024138042A1 (en) 2022-12-22 2024-06-27 Xinthera, Inc. Alpha4 beta7 integrin antagonists and uses thereof
TW202448866A (zh) * 2023-02-21 2024-12-16 英商Ｃ4Ｘ探索有限公司 治療性化合物
IL324720A (en) 2023-05-26 2026-01-01 Adarx Pharmaceuticals Inc SOD1 modulators and methods of using them
WO2025026955A1 (en) * 2023-07-28 2025-02-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2024317579A1 (en) 2023-07-28 2026-02-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Benzo nitrogen-containing heterocyclic derivative regulator, preparation method therefor and use thereof
WO2025176107A1 (zh) * 2024-02-20 2025-08-28 西藏海思科制药有限公司 一种吡啶酮衍生物及其在医药上的应用
CN118702712B (zh) * 2024-07-04 2025-11-11 安徽普利药业有限公司 一种n-(3-苯10硼酸)-l-天冬氨酸中间体制备方法
WO2026018017A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds
WO2026018016A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds
CN119504796B (zh) * 2024-11-20 2026-03-10 南通大学附属医院 一种具有抗肿瘤活性的化合物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721366A (en) 1993-03-31 1998-02-24 G. D. Searle & Co Platelet aggregation inhibitors
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
CA2268381A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
CA2268270A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Heterocyclic derivatives as factor xa inhibitors
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
ES2221227T3 (es) 1997-11-24 2004-12-16 MERCK & CO., INC. Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular.
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
EP1091945A1 (en) 1998-06-29 2001-04-18 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
AU747784B2 (en) * 1998-07-29 2002-05-23 Merck & Co., Inc. Integrin receptor antagonists
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
AU4826900A (en) * 1999-05-07 2000-11-21 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
ATE364592T1 (de) 1999-09-24 2007-07-15 Genentech Inc Tyrosinderivate
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
PL365729A1 (en) * 2000-08-30 2005-01-10 Pharmacia Corporation Gem-substituted alpha v beta 3 integrin antagonists
DE10111876A1 (de) 2001-03-10 2002-09-19 Aventis Pharma Gmbh Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe
DE10154280A1 (de) 2001-11-05 2003-05-15 Wilex Ag Antagonisten für alpha¶4¶-Integrine
SI1485127T1 (sl) 2002-02-25 2011-09-30 Elan Pharm Inc Dajanje aktivne snovi za zdravljenje vnetja
WO2006026759A2 (en) 2004-09-03 2006-03-09 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
ES2387317T3 (es) 2005-03-03 2012-09-20 Seedlings Life Science Ventures, Llc. Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
DE602006019731D1 (de) 2005-06-09 2011-03-03 Ucb Pharma Sa 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel
HUE047230T2 (hu) 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
WO2010091411A1 (en) 2009-02-09 2010-08-12 Glaxosmithkline Llc Piperidinyl cyclic amido antiviral agents
KR20130137688A (ko) 2011-03-31 2013-12-17 제넨테크, 인크. 베타7 인테그린 길항제를 투여하는 방법
KR101850591B1 (ko) 2012-10-05 2018-04-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
MA39804A (fr) 2014-03-27 2017-02-01 Hoffmann La Roche Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin
WO2016011940A1 (zh) 2014-07-25 2016-01-28 江苏恒瑞医药股份有限公司 氮茚-酰胺类衍生物、其制备方法及其在医药上的应用
EP3581585A1 (en) * 2014-11-26 2019-12-18 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
EP3978530A1 (en) 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
SG11201907820SA (en) * 2017-02-28 2019-09-27 Morphic Therapeutic Inc Inhibitors of (alpha-v)(beta-6) integrin
US10246451B2 (en) 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
CN112312910A (zh) 2018-04-12 2021-02-02 莫菲克医疗股份有限公司 人整合素α4β7拮抗剂
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
US11179383B2 (en) * 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
AU2020366435A1 (en) 2019-10-16 2022-04-21 Morphic Therapeutic, Inc. Inhibiting human integrin α4β7

Also Published As

Publication number Publication date
MA57399B1 (fr) 2025-06-30
ZA202303992B (en) 2024-06-26
PY2065718A (es) 2023-01-17
DOP2022000081A (es) 2022-07-31
CU20220027A7 (es) 2022-12-12
SI4045039T1 (sl) 2025-07-31
CN115087444B (zh) 2024-09-17
TWI888065B (zh) 2025-06-21
JP2022548809A (ja) 2022-11-22
AU2020366435A1 (en) 2022-04-21
CA3154269A1 (en) 2021-04-22
ECSP22038978A (es) 2022-06-30
TW202332675A (zh) 2023-08-16
CO2022005759A2 (es) 2022-05-20
FI4045039T3 (fi) 2025-06-20
JP2024054293A (ja) 2024-04-16
JP2023500437A (ja) 2023-01-06
DK4045039T3 (da) 2025-06-30
TW202126624A (zh) 2021-07-16
EP4045039A1 (en) 2022-08-24
US11104661B1 (en) 2021-08-31
KR20230088376A (ko) 2023-06-19
MD4045039T2 (ro) 2025-11-30
JP2024054296A (ja) 2024-04-16
JP2022542184A (ja) 2022-09-29
IL292296A (en) 2022-06-01
AU2021361031A1 (en) 2023-06-08
JP7437490B2 (ja) 2024-02-22
EP4559525A2 (en) 2025-05-28
TWI791304B (zh) 2023-02-01
HRP20250749T1 (hr) 2025-08-15
IL292296B1 (en) 2025-03-01
US20240174632A1 (en) 2024-05-30
MX2022004406A (es) 2022-08-25
IL319053A (en) 2025-04-01
KR20220102669A (ko) 2022-07-20
EP4559525A3 (en) 2025-08-20
TW202500559A (zh) 2025-01-01
TWI900200B (zh) 2025-10-01
WO2021076890A4 (en) 2021-06-10
TWI775182B (zh) 2022-08-21
ZA202203872B (en) 2024-01-31
US11370773B1 (en) 2022-06-28
TW202315868A (zh) 2023-04-16
TW202222793A (zh) 2022-06-16
TWI857592B (zh) 2024-10-01
AR120244A1 (es) 2022-02-09
JP7702004B2 (ja) 2025-07-02
ES3035561T3 (en) 2025-09-04
CR20220205A (es) 2022-07-22
WO2021076890A1 (en) 2021-04-22
CN116783161B (zh) 2026-04-03
BR112022007284A2 (pt) 2022-07-05
RS66976B1 (sr) 2025-07-31
JP2023036958A (ja) 2023-03-14
WO2021076902A1 (en) 2021-04-22
UY38926A (es) 2021-05-31
JP7717202B2 (ja) 2025-08-01
JP7437495B2 (ja) 2024-02-22
TWI802477B (zh) 2023-05-11
CL2022000959A1 (es) 2023-04-28
EP4228634A1 (en) 2023-08-23
IL292296B2 (en) 2025-07-01
WO2022081983A1 (en) 2022-04-21
CN115087444A (zh) 2022-09-20
LT4045039T (lt) 2025-08-11
TW202500558A (zh) 2025-01-01
HUE071814T2 (hu) 2025-09-28
EP4045039A4 (en) 2023-12-13
EP4228634A4 (en) 2024-12-18
EP4045039B1 (en) 2025-04-23
TW202244040A (zh) 2022-11-16
CN119192137A (zh) 2024-12-27
JP2024116230A (ja) 2024-08-27
CN116783161A (zh) 2023-09-19
PH12022550886A1 (en) 2023-05-03
PL4045039T3 (pl) 2025-09-15
JP7500785B2 (ja) 2024-06-17
TWI840047B (zh) 2024-04-21
JP7209116B2 (ja) 2023-01-19
DOP2025000034A (es) 2025-04-08
UA130059C2 (uk) 2025-10-29
PT4045039T (pt) 2025-07-02

Similar Documents

Publication Publication Date Title
HRP20250749T1 (hr) Inhibirajući ljudski integrin alfa-4 beta-7
AR076219A1 (es) Analogos de isoxazol-3 (2h)-ona como agentes terapeuticos
ME02892B (me) Hemijska jedinjenja
AR059590A1 (es) Inhibidores de quinasa basados en la hidantoina
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
NZ707083A (en) Anti-fibrotic pyridinones
IL321451A (en) Compositions and methods of modulating short-chain dehydrogenase activity
PE20142461A1 (es) Moduladores del receptor de estrogeno y sus usos
AR093937A1 (es) Compuestos quimicos
MX375073B (es) Cristal de acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico.
HRP20161103T1 (hr) Kemijski spojevi
MA38540B1 (fr) Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6
IN2014DN03063A (enExample)
AR083180A1 (es) Amidas de oxopiperazina-azetidina y amidas oxodiazepina-azetidina como inhibidores de monoacilglicerol lipasa
EA201691071A1 (ru) Фенилтриазолопиридиновые соединения
CA2956045A1 (en) Carboxylic acid compound, method for preparation thereof, and use thereof
WO2014128545A3 (en) An improved process for the preparation of dolutegravir
MY172860A (en) Dimethyl-benzoic acid compounds
EP2922812A4 (en) METHOD FOR PRODUCING A SALT FROM A SULFURIZED HYDROXYAROMATIC ALKYL SUBSTITUTED COMPOSITION
EA201690879A1 (ru) Новое триазолопиридиновое соединение
JP2016518448A5 (enExample)
EA201492255A1 (ru) Феноксиэтилпиперидиновые соединения
AR081893A1 (es) Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina
EA201391537A1 (ru) ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5
AR086113A1 (es) Isoxazolinas como agentes terapeuticos